Canada markets closed

Evofem Biosciences, Inc. (EVFM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0690+0.0109 (+18.76%)
At close: 03:59PM EST

Evofem Biosciences, Inc.

12400 High Bluff Drive
Suite 600
San Diego, CA 92130
United States
858 550 1900
https://www.evofem.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees119

Key Executives

NameTitlePayExercisedYear Born
Ms. Saundra PelletierInterim Chair, Pres & CEO1.23MN/A1970
Mr. Justin J. FileChief Financial Officer809.24kN/A1970
Ms. Amy RaskopfSr. VP of Investor RelationsN/AN/AN/A
Kathy Gallo-DoyleVP of SalesN/AN/AN/A
Ms. Karina M. FedaszHead of Bus. Devel.N/AN/A1973
Ms. Katherine AtkinsonChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Corporate Governance

Evofem Biosciences, Inc.’s ISS Governance QualityScore as of November 28, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.